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Abstract
A novel glucose transporter, the sodium glucose cotransporter 2 (SGLT2), has been demonstrated to contribute to the demand 
for glucose by pancreatic and prostate tumors, and its functional activity has been imaged using a SGLT specific PET imag-
ing probe, α-methyl-4-[F-18]fluoro-4-deoxy-d-glucopyaranoside (Me-4FDG). In this study, Me-4FDG PET was extended to 
evaluate patients with high-grade astrocytic tumors. Me-4FDG PET scans were performed in four patients diagnosed with 
WHO Grade III or IV astrocytomas and control subjects, and compared with 2-deoxy-2-[F-18]fluoro-d-glucose (2-FDG) 
PET and magnetic resonance imaging (MRI) of the same subjects. Immunocytochemistry was carried out on Grade IV 
astrocytomas to determine the cellular location of SGLT proteins within the tumors. Me-4FDG retention was pronounced in 
astrocytomas in dramatic contrast to the lack of uptake into the normal brain, resulting in a high signal-to-noise ratio. Macro-
scopically, the distribution of Me-4FDG within the tumors overlapped with that of 2-FDG uptake and tumor definition using 
contrast-enhanced MRI images. Microscopically, the SGLT2 protein was found to be expressed in neoplastic glioblastoma 
cells and endothelial cells of the proliferating microvasculature. This preliminary study shows that Me-4FDG is a highly 
sensitive probe for visualization of high-grade astrocytomas by PET. The distribution of Me-4FDG within tumors overlapped 
that for 2-FDG, but the absence of background brain Me-4FDG resulted in superior imaging sensitivity. Furthermore, the 
presence of SGLT2 protein in astrocytoma cells and the proliferating microvasculature may offer a novel therapy using the 
SGLT2 inhibitors already approved by the FDA to treat type 2 diabetes mellitus.
Keywords Astrocytomas · SGLT2 · PET imaging
Introduction
Cancer cells require high amounts of glucose as an energy 
source to grow and proliferate and this is the basis for posi-
tron emission tomography (PET) imaging with 2-deoxy-
2-[F-18]fluoro-d-glucose (2-FDG) to detect and stage 
tumors. 2-FDG enters tumors via the facilitated glucose 
transporter GLUT1 (SLC2A1) where it accumulates follow-
ing phosphorylation to 2-FDG-6-phosphate (2-FDG-6-P). In 
most cases, the high differential uptake of 2-FDG in cancer 
cells relative to that of surrounding tissues provides excel-
lent imaging sensitivity.
For brain tumors, the level of 2-FDG-6-P accumula-
tion depends on the density of GLUT1 transporters, the 
rate of hexokinase mediated 2-FDG phosphorylation, and 
the restricted efflux of 2-FDG-6-P from cells. In brain, the 
high rate of 2-FDG uptake in grey matter reduces tumor/
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background contrast and limits the utility of 2-FDG PET 
for imaging tumors.
In addition to the GLUT pathway for glucose uptake into 
cells, there is a second major class of glucose transport-
ers known as the sodium glucose cotransporters (SGLTs or 
SLC5s) [1]. SGLT1 is expressed in the intestine and kidney, 
whereas SGLT2 is exclusively expressed in the kidney where 
it is responsible for glucose reabsorption from the glomeru-
lar filtrate. SGLT2 inhibitors, called glifozins, have gained 
recent clinical acceptance for the treatment of diabetes mel-
litus [2].
To assess the importance of this alternate glucose trans-
port pathway in the body, we designed a new PET molecu-
lar imaging probe, α-methyl-4-[F-18]fluoro-4-deoxy-d-glu-
copyranoside (Me-4FDG) that is not a substrate for GLUTs 
[3]. The design of Me-4FDG was based on the knowledge 
that α-methyl-d-glucopyranoside is a non-metabolized sub-
strate for SGLTs that is pumped into cells using the sodium 
concentration gradient across the cell membrane as a driv-
ing force.
We have previously reported on the importance of SGLT2 
expression in pancreatic and prostate adenocarcinomas 
[4]. Here in a preliminary study, we report that SGLT2 is 
expressed in WHO Grade III and IV astrocytomas and that 
Me-4FDG PET provides a new high contrast metabolic 
imaging approach to detect and evaluate high-grade glio-
mas. This provides an entry into the understanding of the 
role SGLT-mediated glucose uptake pathway in astrocytoma 
growth and progression.
Materials and methods
Subjects
The preliminary study was performed, in compliance with 
guidelines set by the UCLA Institutional Review Board, on 
four adult brain tumor patients, and one adult with a history 
of epilepsy (Table 1). Three patients were newly diagnosed 
with WHO Grade IV astrocytomas (glioblastomas), and one 
newly diagnosed with a WHO Grade III (anaplastic) astro-
cytoma [5]. Their UCLA physician referred all patients and 
they, along with the healthy volunteers, gave their written 
informed consent. Table 1 summarizes the demographics, 
imaging and pathology findings of the four tumor patients, 
and the patient with a history of epilepsy, who for the pur-
pose of this study is considered as a control subject. The 
tumor patients underwent clinical 2-FDG and MRI imaging 
(T1-weighted MP-RAGE with and without gadolinium con-
trast), and an experimental Me-4FDG PET scan 1 day prior 
to surgery. The epilepsy subject underwent clinical MRI, 
and interictal 2-FDG and Me-4FDG PET scans. Clinical 
evaluations of the 2-FDG and MRI scans in this subject were 
unremarkable with no localizing evidence for an epilepto-
genic focus.
As SGLT2 antibodies were not yet available at the 
time of the Me-4FDG PET studies, SGLT2 and SGLT1 
immunochemistry (IHC) was subsequently carried out 
on 5 age-matched WHO Grade IV glioblastoma speci-
mens selected from the UCLA Brain Tissue Translational 
Resource (Table 2). Suitable frozen archival sections were 
not available for the original PET patients. A board-certi-
fied neuropathologist (WHY) examined each slide used for 
immunohistochemistry (IHC) to confirm the presence of 
astrocytoma.
PET imaging
Me-4FDG was prepared as previously described from 
nucleophilic fluorination of its precursor methyl 2,3,6-tri-
O-acetyl-4-O-triflyl-α-d-galactopyranoside using cyclotron-
produced [F-18]fluoride [3]. The pure non-carrier added 
final product in saline solution and suitable for injection 
into humans had > 97% chemical and radiochemical purity 
and high specific activity (> 2000 Ci/mmol). All subjects 
received ~ 370 MBq (~ 10 mCi) of Me-4FDG (10.4 ± 1.6 µCi, 
range: 8.3–11.7 mCi) as a bolus injection via an indwelling 
venous catheter. Scans on astrocytoma and epilepsy patients 
(2-FDG and Me-4FDG) and healthy controls (Me-4FDG) 
were carried out on a Siemens/CTI ECAT Exact HR + PET 
or a Siemens Biograph PET/CT scanner.
Nine healthy volunteers without brain tumors or history 
of neurodegenerative disorders (7 males and 2 females aged 
24–79) were recruited and underwent whole body Me-4FDG 
PET scans from the top of the head to mid-thigh. The first 
five scans were 10 min each, and the last three were 20 min 
each with total duration of 110 min. These scans were per-
formed to determine bio-distribution of Me-4FDG in the 
brain and other organs over time.
Two tumor patients underwent brain PET scans after 
30 min uptake time (consisting of four 300 s frames), and 
two were subjected to dynamic brain PET scans starting at 
the time of injection. In one case for 49 min (six 30 s frames, 
four 180 s frames, three 600 s frames and one 225 s frame), 
and the other case for 125 min (six 30 s frames, four 180 s 
frames, five 600 s frames, and three 1200 s frames).
The brain tumor patients and the epilepsy patient also 
underwent clinical 2-FDG brain PET scans as a component 
of their diagnostic work-ups, using a standard clinical pro-
tocol (180 MBq of 2-FDG, 40 min uptake time followed by 
20 min head PET scan) [6].
Attenuation correction was performed using data from 
appropriate transmission scans using retractable [Ge-68]/
[Ga-68] rods (ECAT HR + PET scanner) or CT imag-
ing (PET/CT scanner). The acquired PET data covering a 
15.5-cm in axial field of view was reconstructed using a 
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filtered-backprojection method (after correction for attenu-
ation, dead time, scatter and decay) with a Hanning filter 
(cutoff frequency, 0.3 cycle per projection element) into 
128 × 128 × 63 matrices. The in-plane spatial resolution of 
the resulting brain images was ∼ 2.5 mm in full width at half 
maximum (5.5 mm for the whole-body scans).
Dynamic and static PET images were analyzed using the 
AMIDE software [7]. 3D regions of interest (ROI) were 
placed over the tumor, the torcula (confluence of sinuses) to 
determine blood activity, and on the hemisphere remote from 
the tumor covering both white and gray matter to determine 
the brain background (BG). As the Me-4FDG scans over 
remote areas from the tumor have a uniformly low signal, we 
cannot distinguish between grey and white matter. Values for 
all time points after 30 min within each ROI were summed 
and the resulting numbers for the tumor were divided by the 
summed number from the torcula ROI to give the SUVR, 
the tumor activity relative to venous blood, and the signal to 
noise (S/N) for the tumor relative to BG for white and grey 
matter. Tumor voxels with at least 90% of maximum value 
within the tumor ROI were used for calculation of the mean 
 SUVRpeak value. Future dynamic studies will be conducted 
to extract the kinetic parameters of Me-4FDG uptake into 
tumors [8].
Immunocytochemistry
SGLT2 is expressed in pancreatic and prostate adenocarci-
nomas [4], and so we reasoned that it may also be responsi-
ble for Me-4FDG uptake into brain tumors. The same poly-
clonal antibodies against SGLT2 (and SGLT1) were used 
to probe SGLT expression in the tumor bank frozen astro-
cytoma specimens. The SGLT antibodies did not recognize 
SGLT1 and SGLT2 in the paraffin sections retained from 
the tumors excised from the PET patients. The SGLT2 anti-
body was raised against a peptide corresponding to residues 
591‒609 of human SGLT2, and the SGLT1 antibody was 
raised against a synthetic peptide corresponding to residues 
563‒575 of human SGLT1. These antibodies were specific 
for SGLT2 and SGLT1 respectively as judged by Western 
Blotting and IHC on control tissues [4, 9–11]. The antibod-
ies for the CD68 (mouse, DakoCytomation, M0876), GFAP 
(mouse, DakoCytomation, M0761), and CD163 (mouse, 
Cell Marque, 163M-16) markers were from commercial 
vendors; the dilutions used were 1/200, 1/200, and 1/50, 
respectively.
For the immunohistochemistry on 4 µm-thick frozen 
sections, the SGLT protocols were identical to those used 
recently for pancreatic and prostate tumors [4]. Antigen 
retrieval was performed: For CD68 by treatment in a pres-
sure cooker in 0.05 M Tris (pH 9.0); for CD163 by treat-
ment for 25 min in a vegetable steamer at 95 °C for 25 min 
in 0.001 M EDTA (pH 8.0, Invitrogen); and for GFAP by 
treatment for 25 min in a vegetable steamer at 95 °C in 
10 mM citrate buffer (pH 6.0). Endogenous peroxidase 
was blocked by incubation with 0.3%  H2O2 for 30 min, 
followed by washes in PBS and incubation for 30 min in 
blocking buffer (5% donkey serum, 0.1%  NaN3 in PBS). 
Incubation with the antibodies with tissue sections was car-
ried out overnight at 4 °C (SGLT2 and CD68) or at room 
temperature (SGLT1). For GFAP and CD163, the primary 
antibody was incubated for 1 h at room temperature. After 
washes, the samples were incubated with secondary anti-
body (Biotin-conjugated Donkey Anti-Rabbit antibody, 
Jackson Immunoresearch) for 90 min at room temperature 
and then with avidin/biotinylated enzyme complex (R.T.U. 
ABC Vectastain kit, Vector Laboratories) for 90 min at room 
temperature, followed by washes and incubation with the 
diaminobenzidine (DAB) substrate (Sigma) for 20 min. For 
CD163, CD68, and GFAP the secondary antibody (Envision 
System HRP-Labelled Polymer, anti-mouse, DakoCytoma-
tion) was incubated for 30 min, followed by DAB incubation 
for 5 min. Counterstaining was performed with diluted (1/5 
in water) Harris hematoxylin (Sigma) and acid eosin. All 
microscopic slides were scanned with Aperio ScanScope 
AT scanner for analysis.
Results
Representative co-registered trans-axial sections of the Me-
4FDG, 2-FDG and contrast MRI scans on the control subject 
(diagnosed with epilepsy) are shown in Fig. 1. The subject 
did not have any seizures on the days of the scans and clini-
cal evaluation of the 2-FDG scan was unremarkable with no 
localizing evidence for an epileptogenic focus. The accumu-
lation of 2-FDG in the cortical gyri, subcortical nuclei, and 
cerebellum was read as normal. There was no significant 
uptake of Me-4FDG into any cortical or subcortical region 
of the brain with only a light Me-4FDG signal coinciding 
with the ventricles, sub-dural spaces, and the superior sagit-
tal sinus. Similar Me-4FDG PET brain images were obtained 
for 9 healthy control human subjects (S/N 0.09 ± 0.02) and 
rodents [9, 10] demonstrating that SGLT transporters are not 
active in the blood-brain-barrier (BBB).
Figure 2 illustrates representative co-registered Me-4FDG 
PET, MRI and 2-FDG PET brain scans from two patients 
with WHO Grade IV astrocytomas. The 57-year-old male 
patient (Fig. 2a) had a 46-mm enhancing mass in the pos-
terior corpus callosum with a non-enhancing necrotic core. 
There was an additional 6 mm-solid enhancing mass in the 
left parietal white matter. Both the 2-FDG and Me-4FDG 
studies showed a high uptake of the respective tracers in 
both tumors largely corresponding to gadolinium uptake, 
but not the necrotic core of the larger tumor. There was nor-
mal 2-FDG activity, and no Me-4FDG activity throughout 
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the remainder of the cortex, white matter, basal ganglia, 
thalamus and cerebellum. The PET scan shows that Me-
4FDG was accumulated in the metabolically active regions 
of tumors. For the larger tumor, the Me-4FDG  SUVRpeak 
value was 1.67 and the signal to noise ratio (S/N) was 11.5, 
and for the smaller mass  SUVRpeak 0.84 and S/N 7.3. There 
was very low background signal elsewhere in the brain (S/N 
0.09).
Figure 2b shows brain images of the 70-year-old male 
patient with a 53-mm peripherally enhancing glioblastoma 
mass in the left parietal lobe. The 2-FDG PET showed 
increased uptake in only the medial portion of the tumor, 
with the lateral gadolinium-enhancing portion having lower 
2-FDG uptake than contralateral hemisphere gray matter. 
There was significant hypometabolism in the surrounding 
peritumoral cortex extending to the super left occipital lobe 
and left posterior cingulate gyrus (not shown). The regional 
uptake of Me-4FDG into the tumor closely resembles that 
for 2-FDG and the contrast MRI. The Me-4FDG  SUVRpeak 
was 2.42 and S/N 16.7. From a clinical imaging perspective, 
the Me-4FDG-PET was superior to 2-FDG as in the latter 
most of the peripheral tumor uptake was equal to that of the 
surrounding gray matter. In both patients, Fig. 2a, b, there 
was high Me-4FDG uptake in the extracranial temporalis 
muscle  [SUVRpeak 1.85 ± 0.55 (6)]. This is consistent with 
SGLT-mediated Me-4FDG uptake into muscles throughout 
the body [1].
Figure 3 shows the Me-4FDG PET and MRI scans for 
a 67-year-old female patient with a 27 mm WHO Grade 
IV astrocytoma in the left posterior frontal lobe. The MRI 
scan indicates the presence of blood vessels within the 
mass, and the tissue pathology shows a branching vascular 
network with endothelial hyperplasia (not shown). 2-FDG 
PET demonstrated uniform accumulation in the tumor (not 
shown). Me-4FDG was uniformly accumulated in the mass 
to a level significantly higher than the surrounding grey and 
white matter. The Me-4FDG values were  SUVRpeak was 1.57 
and S/N 16.6.
Figure 4 shows the results of studies on a 42-year-old 
male patient with a heterogeneously enhancing 56 mm 
WHO Grade III astrocytoma. The tumor and surrounding 
edema caused significant mass effect and midline shift. On 
the 2-FDG PET scan, there was mixed uptake within some 
portions of the mass in the left insula and left temporal lobe. 
The highest tumor 2-FDG uptake was comparable to the 
normal uptake into the gyri of the right hemisphere and cer-
ebellum. There was in contrast a uniform Me-4FDG uptake 
into the tumor  (SUVRpeak was 2.55 and S/N 10.9) but none 
anywhere else in the brain (S/N 0.07). From a clinical diag-
nostic perspective, the 2-FDG PET was of minimal utility, 
whereas the Me-4FDG PET would have been far superior.
In the two cases with dynamic PET scans the uptake of 
Me-4FDG in the tumor exceeded that in venous blood (tor-
cula) within 15–20 min and remained stable for the rest of 
the scan (data not shown). The SUVR (the ratio of activity 
in the tumor to that in venous blood) changed from 0.4 to 
0.5 in the first 2 min to 1.27 and to 1.60 at 30 min. This 
demonstrates that the Me-4FDG within the tumor at 30 min 
comes from tumor uptake and only partially comes from 
the blood pool. The background value for the brain paren-
chyma (S/N ratio of activity in normal brain to torcula) was 
0.09 ± 0.02 (n = 6), which is consistent with the nominal 
Fig. 1  Me-4FDG, MRI, and 2-FDG PET scans on 26-year-old control subject. The Me-4FDG S/N (SUVR/BG) scale 0–10 is shown for the NIH 
color scale, and the 2-FDG SUVR scale is 0.1–2.5 for the Hot-Iron color scale
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vascular volume in brain tissue. The S/N ratio obtained from 
the whole-body PET scans in the nine control subjects was 
higher, 0.32 ± 0.08, and this can be partially attributed to an 
underestimation of the torcula values.
SGLT immunohistochemistry
This was carried out on recent flash frozen specimens, as 
the antibodies did not recognize SGLTs in paraffin embed-
ded normal kidney and in the glioblastoma specimens pre-
served from the PET patients. Figure 5 shows a typical 
case of a WHO Grade IV glioblastoma with high cellu-
larity, with diffuse SGLT2 cellular staining in many neo-
plastic cells, but SGLT1 was restricted to the cell nuclei. 
The specificity of SGLT staining was confirmed in adja-
cent sections where the antibodies staining was blocked 
by the antigenic peptides used to raise the antibodies. At 
higher magnification (Panels E &F) specific SGLT2 labe-
ling was evident in, or close to, the plasma membrane. 
At the resolution of light microscopy, it is not possible to 
resolve antibody staining between the cytoplasm and the 
cell membrane.
Fig. 2  Me-4FDG PET, 2-FDG PET, and MRI scans on WHO Grade 
IV astrocytoma patients. a Patient with a 46-mm posterior corpus cal-
losum astrocytoma, and b patient with 53-mm posterior para median 
left parietal lobe glioblastoma. For Me-4FDG the S/N (SUVR/BG) 
the NIH color scales are those relative to the torcula, and for 2-FDG 
the SUVR scales are for the “Hot-Iron” color scale. SUVR for 2-FDG 
was based on white matter as reference region and not blood. SUVR 
for Me-4FDG was based on blood activity and we re-normalized it to 
brain tissue so that we actually are comparing the same values. Thus, 
that is why S/N is specified for Me-4FDG and SUVR is specified for 
2-FDG in the scale bar
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SGLT2 protein was also detected in the thin endothelium 
lining areas of tumor microvasculature (Fig. 6). This obser-
vation was surprising, because SGLTs are absent from nor-
mal brain capillary endothelium [9, 10], resulting in the lack 
of Me-4FDG penetration into the brain.
We next wanted to exclude that SGLT2 was expressed 
only in glial cells infiltrating the diseased tissue; therefore, 
we stained adjacent sections with antibodies specific for 
microglia (CD68 and CD163) and for astrocytes (GFAP). 
Figure 7 presents a representative sample in which hema-
toxylin and eosin staining shows a WHO Grade IV glio-
blastoma with high cellularity (see also Fig. 5). CD68 and 
CD163 were positive in sparse cells, mostly in perivascu-
lar spaces, consistent with a microglial origin of the posi-
tive cells (Fig. 7d, e); both the endothelial cells and the 
perivascular microglial elements are positive for SGLT2 
(Fig. 6c). The SGLT2 signal was specific, as it was com-
pletely abrogated by pre-incubation of the antibody with 
the antigenic peptide (Fig. 7c). Finally, GFAP shows dif-
fuse positivity, consistent with the glial origin of the neo-
plastic cells. Taken together, these data showed that SGL2 
is expressed in different elements of the tumor: malignant 
glioma cells, endothelial cells, and microglial cells.
Fig. 3  Me-4FDG PET and MRI 
scans on a WHO Grade IV 
astrocytoma patient. The Me-
4FDG S/N (SUVR/BG) scale is 
for the NIH color scale
Fig. 4  Me-4FDG PET, 2-FDG PET and MRI scans on a patient with an anaplastic astrocytoma (WHO Grade III). The Me-4FDG S/N (SUVR/
BG) scales are for the NIH color scale and the 2-FDG SUVR scale is for the “Hot-Iron” color scale
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Fig. 5  Expression of SGLT1 and SGLT2 in glioblastoma cells. A rep-
resentative sample of human glioblastoma (WHO Grade IV) involv-
ing the left frontal lobe, typically characterized by high cellularity, 
was stained SGLT1, showing mostly nuclear signal (a); SGLT2, 
showing both nuclear and cytoplasmic staining in tumor cells (c). 
SGLT1 + antigenic peptide (b); and SGLT2 + antigenic peptide (d). A 
higher magnification image showing SGLT2 in or close to the plasma 
membrane (e, red arrowheads), and block by the antigenic peptide (f)
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No tumor was evident in the IHC slides provided for in 
one WHO Grade IV tumor sample (#1 Table 2). These con-
tained normal gray and white matter with a reactive gliosis. 
There was weak specific SGLT1 staining in neurons and/
or astrocytes. SGLT2 specific staining occurred in reactive 
astocytes and neurons, but none was evident for SGLT2 and 
SGLT1 in the microvessels.
Discussion
This study introduces Me-4FDG PET as a novel, comple-
mentary, and in some respects superior clinical imaging 
modality for patients with high-grade astrocytomas. In 
each of the four high-grade astrocytoma patients imaged, 
the tumors avidly accumulated the Me-4FDG in stark con-
trast to the surrounding brain tissue. We readily acknowl-
edge that, given the small study sample size, the potential 
clinical utility is not definable at this time, and further 
studies will be required to assess the utility of Me-4FDG 
PET in patients with molecular subtypes of glioblastoma, 
lower grade gliomas, and other glioma types.
In this preliminary study, the imaging characteristics 
visualized using Me-4FDG PET are superior to those of 
2-FDG PET in brain tumors. Coupled with very low back-
ground levels of activity due to lack of SGLT expression 
on normal BBB, the observed Me-4FDG tumor activ-
ity levels were 11–17-fold higher than background and 
1.6–2.6 fold higher than blood in these WHO Grade III 
and IV astrocytoma. The resolution of Me-4FDG PET 
can be gauged by the detection of a 6 mm mass in the 
left partial white matter of the patient with a WHO Grade 
IV tumor in the posterior corpus callosum (Fig. 2a). This 
provides evidence that 6 mm tumors may be detected by 
Me-4FDG PET in patients with other types of cancer, e.g. 
pancreatic adenocarcinomas.
Fig. 6  Expression of SGLT1 and SGLT2 in microvascular prolif-
eration. A representative sample of human glioblastoma showing the 
characteristic, irregularly shaped microvascular proliferation stained 
with a SGLT1, c SGLT2 and b, d with appropriate antigenic peptides. 
Note the intense specific staining of the endothelial cells with the 
SGLT2 antibody
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Fig. 7  Relationship between SGLT2 expression and glial markers. 
Adjacent sections of a human glioblastoma sample were stained with 
different markers: a hematoxylin and eosin (H & E), showing high 
cellularity around a blood vessel; b SGLT2 expression in the vessel 
endothelium, in the microglia/macrophages surrounding the blood 
vessel, and the cancer cells; c negative control with SGLT2 antibody 
after pre-incubation with the antigenic peptide; and glial markers 
CD68 (d) and CD163 (e), showing restricted expression in microglia/
macrophages surrounding the blood vessel, and GFAP (f), showing 
diffuse immune-positivity
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Comparative studies will be required to assess the mer-
its of Me-4FDG relative to other carbon-11 and fluorine-18 
PET probes, such as amino acids (e.g. [C-11]methionine, 
[F-18]FDOPA, [F-18]FET, [F-18]fluciclovine [12–14]), 
or other targets expressed in glioblastomas (e.g. PSMA, 
CXCR4 [15–17]). Amino acid PET tracers exploit increased 
expression of amino acid transporters in tumor cells but their 
sensitivity is affected by the presence of amino acid trans-
porters on normal BBB and other brain structures. The util-
ity of PSMA or CXCR4 ligands is limited to WHO Grade 
IV glioblastomas that express their target proteins on their 
vasculature but not lower Grade astrocytomas that do not 
show such expression [18–20].
There are many questions that need to be addressed based 
on this exploratory study, including Me-4FDG pathobiol-
ogy and tracer dynamics. The subjective co-analysis of MRI 
and Me-4FDG PET imaging revealed that the distribution of 
Me-4FDG uptake generally reflected the deposition of gado-
linium; the latter generally considered reflecting an open-
ing or loss of the BBB. Me-4FDG, unlike 2-FDG, does not 
cross the normal BBB in rodents and human subjects [9, 10] 
indicating that SGLTs are not functional in the endothelial 
plasma membranes of the normal BBB. The PET imaging 
in all cases confirmed that there was no entry of Me-4FDG 
into normal brain. Our demonstration of SGLT2 expression 
in endothelial cells in the proliferative tumor microvascula-
ture suggests that the transporter contributes to Me-4FDG 
transport across the blood–tumor-barrier (BTB).
The results of our preliminary studies support the finding 
that the Me-4FDG within the tumor derives from a com-
bination of tracer within tumor tissue and the blood pool. 
SGLT2 expression in neoplastic cells suggests that sodium 
symport contributes to Me-4FDG uptake within tumor cells. 
Unlike 2-FDG, Me-4FDG is a non-metabolized substrate for 
SGLT2 and accumulation of the tracer in cells is depend-
ent on the density of SGLT2 proteins and the magnitude of 
the inward sodium electrochemical potential gradient [1]. 
Without the active transport of Me-4FDG into the tumor 
tissue one would expect similar activity levels in the tumor 
tissue and the blood pool due to broken blood-tumor barrier. 
Yet we observed an increase in tumor SUVR levels at later 
time points (beyond 15–20 min) when the blood radioactiv-
ity levels drop significantly.
How is Me-4FDG accumulated in glioblastomas? First, 
SGLT2 expression in endothelial cells of the proliferative 
microvasculature suggests that that this transporter may con-
tribute to Me-4FDG transport across the BTB; and second, 
SGLT2 expression in neoplastic cells suggests that sodium 
symport contributes to Me-4FDG uptake.
There are two clinical implications of SGLT2 expression 
in glioblastomas. First, Me-4FDG PET/CT may be a useful 
imaging tool to detect brain tumors, even those as small 
as 6 mm, given the high signal to noise ratio signal for the 
brain. This is an obvious advantage over 2-FDG, as well as 
other carbon-11 and fluorine-18 PET imaging probes (see 
above). Second, SGLT2 inhibitors which have been devel-
oped to lower blood glucose levels in Type 2 diabetes mel-
litus may have a therapeutic potential for astrocytomas [2]. 
These drugs have a high affinity  (Ki 1–5 nM) and specificity 
for SGLT2, e.g. the affinity of empagliflozin for SGLT2 is 
more than 2500-times higher than that for SGLT1.
It will be important to gain an understanding of what 
purpose the alternative SGLT2 mediated glucose uptake 
pathway, as opposed to the GLUT pathway, offers astrocyte 
tumors cells. If SGLT2 transporters on tumor cells provide 
for significant glucose uptake, then pharmacological SGLT2 
blockage may have a starving effect and would disrupt their 
ability to grow and proliferate. In a preclinical trial SGLT2 
inhibitors reduced the rate of growth and increased necrosis 
of a mouse model of pancreatic cancer [4].
We envisage that Me-4FDG PET may be useful in the 
future to image low-grade astrocytomas and other types of 
brain tumors, and may be able to follow the recurrence of 
tumors after therapy.
Conclusions
A new glucose PET tracer, Me-4FDG, may provide highly 
sensitive imaging of high-grade astrocytomas. Me-4FDG, 
a specific substrate for SGLTs, does not cross the BBB and 
is not taken up by the normal brain. However, Me-4FDG 
crosses the BTB and is accumulated in tumors due to the 
expression of SGLT2 in proliferating microvessels and 
neoplastic cells. As a result, the signal to noise ratio for 
Me-4FDG uptake into tumors is superior to that for 2-FDG. 
SGLT2 is the new target for drugs to treat diabetes, and these 
may offer a novel therapeutic approach to treating brain 
tumors.
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